Switch theme
Sign up to access all valuation multiples
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
2009
567
LTM Revenue $111M
LTM EBITDA -$73.3M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ascentage Pharma has a last 12-month revenue (LTM) of $111M and a last 12-month EBITDA of -$73.3M.
In the most recent fiscal year, Ascentage Pharma achieved revenue of $981M and an EBITDA of -$238M.
Ascentage Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascentage Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $111M | XXX | $981M | XXX | XXX | XXX |
| Gross Profit | $105M | XXX | $952M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$73.3M | XXX | -$238M | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | -24% | XXX | XXX | XXX |
| EBIT | -$85.0M | XXX | -$370M | XXX | XXX | XXX |
| EBIT Margin | -77% | XXX | -38% | XXX | XXX | XXX |
| Net Profit | -$86.1M | XXX | -$405M | XXX | XXX | XXX |
| Net Margin | -78% | XXX | -41% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $402M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ascentage Pharma's stock price is $26.
Ascentage Pharma has current market cap of $2.2B, and EV of $2.3B.
See Ascentage Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.2B | XXX | XXX | XXX | XXX | $-1.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ascentage Pharma has market cap of $2.2B and EV of $2.3B.
Ascentage Pharma's trades at 2.3x EV/Revenue multiple, and -9.6x EV/EBITDA.
Equity research analysts estimate Ascentage Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ascentage Pharma has a P/E ratio of -25.9x.
See valuation multiples for Ascentage Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 20.7x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | -31.3x | XXX | -9.6x | XXX | XXX | XXX |
| EV/EBIT | -26.9x | XXX | -6.2x | XXX | XXX | XXX |
| EV/Gross Profit | 21.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -25.9x | XXX | -5.5x | XXX | XXX | XXX |
| EV/FCF | -29.0x | XXX | -16.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAscentage Pharma's last 12 month revenue growth is 57%
Ascentage Pharma's revenue per employee in the last FY averaged $1.7M, while opex per employee averaged $2.3M for the same period.
Ascentage Pharma's rule of 40 is -278% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ascentage Pharma's rule of X is 76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ascentage Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | -44% | XXX | XXX | XXX |
| EBITDA Margin | -66% | XXX | -24% | XXX | XXX | XXX |
| EBITDA Growth | -66% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -278% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 97% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 135% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascentage Pharma acquired XXX companies to date.
Last acquisition by Ascentage Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascentage Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ascentage Pharma founded? | Ascentage Pharma was founded in 2009. |
| Where is Ascentage Pharma headquartered? | Ascentage Pharma is headquartered in United States of America. |
| How many employees does Ascentage Pharma have? | As of today, Ascentage Pharma has 567 employees. |
| Who is the CEO of Ascentage Pharma? | Ascentage Pharma's CEO is Dr. Dajun Yang, M.D.,PhD. |
| Is Ascentage Pharma publicy listed? | Yes, Ascentage Pharma is a public company listed on NAS. |
| What is the stock symbol of Ascentage Pharma? | Ascentage Pharma trades under AAPG ticker. |
| When did Ascentage Pharma go public? | Ascentage Pharma went public in 2025. |
| Who are competitors of Ascentage Pharma? | Similar companies to Ascentage Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ascentage Pharma? | Ascentage Pharma's current market cap is $2.2B |
| What is the current revenue of Ascentage Pharma? | Ascentage Pharma's last 12 months revenue is $111M. |
| What is the current revenue growth of Ascentage Pharma? | Ascentage Pharma revenue growth (NTM/LTM) is 57%. |
| What is the current EV/Revenue multiple of Ascentage Pharma? | Current revenue multiple of Ascentage Pharma is 20.7x. |
| Is Ascentage Pharma profitable? | Yes, Ascentage Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ascentage Pharma? | Ascentage Pharma's last 12 months EBITDA is -$73.3M. |
| What is Ascentage Pharma's EBITDA margin? | Ascentage Pharma's last 12 months EBITDA margin is -66%. |
| What is the current EV/EBITDA multiple of Ascentage Pharma? | Current EBITDA multiple of Ascentage Pharma is -31.3x. |
| What is the current FCF of Ascentage Pharma? | Ascentage Pharma's last 12 months FCF is -$79.1M. |
| What is Ascentage Pharma's FCF margin? | Ascentage Pharma's last 12 months FCF margin is -72%. |
| What is the current EV/FCF multiple of Ascentage Pharma? | Current FCF multiple of Ascentage Pharma is -29.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
